Anti-VEGF Clinical Trials
2 recruitingDrug
Phase 21
Showing 1–2 of 2 trials
Recruiting
Phase 2
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases
Hepatocellular CarcinomaRadiotherapyImmunotherapy+3 more
Shandong Cancer Hospital and Institute54 enrolled1 locationNCT07062055
Recruiting
Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital50 enrolled1 locationNCT06537908